IF GW were managing the company and their resume's, track record and contacts are half of what is documented, would Bioniche be trading higher or lower than $2.50, with the catalysts we have been lead to believe are pending? I would be comfortable saying they could 5 bag the current SP, sitting in Lazy Boys watching the Murder She Wrote catalogue all day long.
Currently there is no value whatsoever attached to the pending AH sale, the possible sale of Health One/VMC, ROW partnerships for Urocidin, Pt. Claire, GMP validation and mosts laughably the meeting with HC. None, not a penny. I don't even think employees are buying to support to the status quo.
But just give them more tome, they are so close, right on the cusp!
The masters of the 31 cent train wreck are who some would have you ride along with. No one cares, and chances are that they will barely care, if and when any of these catalysts begin to turn.